Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R D Hamilton

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Toxicology and Applied Pharmacology|January 6, 1999
The importance of fiber biopersistence and lung dose in determining the chronic inhalation effects of X607, RCF1, and chrysotile asbestos in ratsT W Hesterberg, G A Hart, J Chevalier, et al.
Journal of Interferon Research|January 1, 1982
Comparison between circulating interferon and drug levels following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different animal speciesR D Hamilton, M A Wynalda, F A Fitzpatrick, et al.
Cancer Research|October 1, 1988
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvageJ K Willson, P H Fischer, K Tutsch, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Toxicology and Applied Pharmacology|January 6, 1999
The importance of fiber biopersistence and lung dose in determining the chronic inhalation effects of X607, RCF1, and chrysotile asbestos in ratsT W Hesterberg, G A Hart, J Chevalier, et al.
Journal of Interferon Research|January 1, 1982
Comparison between circulating interferon and drug levels following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different animal speciesR D Hamilton, M A Wynalda, F A Fitzpatrick, et al.
Cancer Research|October 1, 1988
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvageJ K Willson, P H Fischer, K Tutsch, et al.
Pageof 7